fabrizio De Benedetti

List of Publications by Year in Descending Order

246 papers	11,151 citations	57 h-index	100 g-index
307 ext. papers	13,384 ext. citations	5.7 avg, IF	6 L-index

#	Paper	IF	Citations
246	Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the Pharmachild registry.. *Journal of Rheumatology*, **2022**,	4.1	1
245	Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis.. *Frontiers in Immunology*, **2022**, 13, 818630	8.4	0
244	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFN) Monoclonal Antibody. *Blood*, **2021**, 138, 2058-2058	2.2	0
243	Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFN) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases. *Blood*, **2021**, 138, 4195-4195	2.2	0
242	Targeting interferon- in hyperinflammation: opportunities and challenges. *Nature Reviews Rheumatology*, **2021**, 17, 678-691	8.1	5
241	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2021**, 73, 1264-1274	4.7	0
240	Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts. *Frontiers in Immunology*, **2021**, 12, 656407	8.4	1
239	Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma. *Frontiers in Immunology*, **2021**, 12, 663329	8.4	3
238	Reumatologia. *Medico E Bambino*, **2021**, 40, 1-3	0.4	
237	Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients. *European Journal of Immunology*, **2021**, 51, 206-219	6.1	14
236	IgM on the surface of T cells: a novel biomarker of pediatric-onset systemic lupus erythematosus. *Pediatric Nephrology*, **2021**, 36, 909-916	3.2	1
235	A rare cause of multiple airways narrowing in a 15-year-old girl. *Thorax*, **2021**, 76, 205-207	7.3	
234	Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic´Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2021**, 73, 1053-1061	9.5	8
233	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. *Rheumatology*, **2021**, 60, 3799-3808	3.9	5
232	Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. *Arthritis and Rheumatology*, **2021**, 73, 530-541	9.5	8
231	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. *Rheumatology*, **2021**, 60, 4568-4580	3.9	5
230	Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. *Lancet Rheumatology, The*, **2021**, 3, e563-e573	14.2	3

229	Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children. *Blood Purification*, **2021**, 1-8	3.1	0
228	Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis. *Pediatric Rheumatology*, **2021**, 19, 123	3.5	1
227	CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REAL-LIFE DATA FROM A RETROSPECTIVE ITALIAN COHORT. *Rheumatology*, **2021**,	3.9	1
226	Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. *Pediatric Rheumatology*, **2021**, 19, 144	3.5	0
225	Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients. *Microorganisms*, **2020**, 8,	4.9	1
224	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. *New England Journal of Medicine*, **2020**, 382, 1811-1822	59.2	161
223	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. *Clinical Infectious Diseases*, **2020**, 71, 2272-2275	11.6	55
222	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. *Annals of the Rheumatic Diseases*, **2020**, 79, 1362-1369	2.4	18
221	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study. *Biologics: Targets and Therapy*, **2020**, 14, 13-21	4.4	2
220	A patient with stimulator of interferon genes-associated vasculopathy with onset in infancy without skin vasculopathy. *Rheumatology*, **2020**, 59, 905-907	3.9	5
219	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. *Arthritis Research and Therapy*, **2020**, 22, 71	5.7	9
218	Translating IL-6 biology into effective treatments. *Nature Reviews Rheumatology*, **2020**, 16, 335-345	8.1	164
217	OP0290 EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). *Annals of the Rheumatic Diseases*, **2020**, 79, 180.1-180	2.4	4
216	OP0272 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL. *Annals of the Rheumatic Diseases*, **2020**, 79, 169.2-170	2.4	
215	AB1059 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL□S DISEASE. *Annals of the Rheumatic Diseases*, **2020**, 79, 1819.2-1820	2.4	0
214	Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. *Frontiers in Pediatrics*, **2020**, 8, 576912	3.4	7
213	Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis. *Frontiers in Genetics*, **2020**, 11, 937	4.5	6
212	Response to: Correspondence on Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial by Satis. *Annals of the Rheumatic Diseases*, **2020**,	2.4	

211	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. *Arthritis Research and Therapy*, **2020**, 22, 211	5.7	2
210	On the Alert for Cytokine Storm: Immunopathology in COVID-19. *Arthritis and Rheumatology*, **2020**, 72, 1059-1063	9.5	394
209	Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2020**, 79, 960-968	2.4	12
208	Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study. *Clinical and Experimental Rheumatology*, **2020**, 38, 1016-1020	2.2	2
207	The activating p.Ser466Arg change in STAT1 causes a peculiar phenotype with features of interferonopathies. *Clinical Genetics*, **2019**, 96, 585-589	4	3
206	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. *Frontiers in Pharmacology*, **2019**, 10, 918	5.6	13
205	Emergent high fatality lung disease in systemic juvenile arthritis. *Annals of the Rheumatic Diseases*, **2019**, 78, 1722-1731	2.4	61
204	Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency. *Journal of Rheumatology*, **2019**, 46, 523-526	4.1	17
203	An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. *Pediatric Rheumatology*, **2019**, 17, 25	3.5	5
202	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. *Journal of Clinical Immunology*, **2019**, 39, 476-485	5.7	43
201	Classification criteria for autoinflammatory recurrent fevers. *Annals of the Rheumatic Diseases*, **2019**, 78, 1025-1032	2.4	159
200	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. *Journal of Rheumatology*, **2019**, 46, 1117-1126	4.1	9
199	Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases **2019**, 751-774		
198	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2019**, 71, 1976-1984	9.5	5
197	Different responses of PC12 cells to different pro-nerve growth factor protein variants. *Neurochemistry International*, **2019**, 129, 104498	4.4	8
196	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. *Journal of Experimental Medicine*, **2019**, 216, 2778-2799	16.6	71
195	NLRP2 Regulates Proinflammatory and Antiapoptotic Responses in Proximal Tubular Epithelial Cells. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 252	5.7	10
194	Anti-interferon-Therapy for Cytokine Storm Syndromes **2019**, 569-580		

193	OP0204 EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) **2019**,		13
192	The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. *PLoS ONE*, **2019**, 14, e0226043	3.7	12
191	Anakinra in children and adults with Still disease. *Rheumatology*, **2019**, 58, vi9-vi22	3.9	42
190	Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?. *Pediatric Rheumatology*, **2019**, 17, 84	3.5	6
189	Interleukin-18 in pediatric rheumatic diseases. *Current Opinion in Rheumatology*, **2019**, 31, 421-427	5.3	11
188	Increased Circulating Levels of Interleukin-6 Affect the Redox Balance in Skeletal Muscle. *Oxidative Medicine and Cellular Longevity*, **2019**, 2019, 3018584	6.7	15
187	Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study. *Arthritis and Rheumatology*, **2019**, 71, 1000-1010	9.5	30
186	Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. *Arthritis and Rheumatology*, **2019**, 71, 1011-1021	9.5	31
185	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. *Clinical and Experimental Rheumatology*, **2019**, 37, 1084-1091	2.2	2
184	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. *Frontiers in Pharmacology*, **2018**, 9, 1526	5.6	6
183	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). *Pediatric Rheumatology*, **2018**, 16, 27	3.5	13
182	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. *Annals of the Rheumatic Diseases*, **2018**, 77, 819-828	2.4	99
181	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). *Rheumatology International*, **2018**, 38, 251-258	3.6	1
180	Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. *Arthritis and Rheumatology*, **2018**, 70, 606-615	9.5	15
179	Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication. *Journal of Rheumatology*, **2018**, 45, 956-961	4.1	10
178	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2018**, 70, 409-419	4.7	72
177	Neutralization of IFN- reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1439-1449	11.5	64
176	In silico validation of the Autoinflammatory Disease Damage Index. *Annals of the Rheumatic Diseases*, **2018**, 77, 1599-1605	2.4	17

175	Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis. *Blood*, **2018**, 132, LBA-6-LBA-6	2.2	13
174	Macrophage Activation Syndrome in Rheumatic Diseases (MAS-HLH) **2018**, 233-246		1
173	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. *Arthritis Research and Therapy*, **2018**, 20, 285	5.7	41
172	Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. *Italian Journal of Pediatrics*, **2018**, 44, 103	3.2	31
171	Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. *Italian Journal of Pediatrics*, **2018**, 44, 102	3.2	45
170	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. *Clinical Rheumatology*, **2018**, 37, 2233-2240	3.9	52
169	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. *New England Journal of Medicine*, **2018**, 378, 1908-1919	59.2	214
168	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. *Journal of Rheumatology*, **2018**, 45, 1173-1179	4.1	6
167	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. *Rheumatology*, **2018**, 57, 1752-1760	3.9	9
166	Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. *Pediatric Rheumatology*, **2017**, 15, 5	3.5	92
165	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. *Lancet, The*, **2017**, 389, 909-916	40	34
164	Development of the autoinflammatory disease damage index (ADDI). *Annals of the Rheumatic Diseases*, **2017**, 76, 821-830	2.4	54
163	Elevated circulating levels of interferon-□and interferon-□nduced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *Annals of the Rheumatic Diseases*, **2017**, 76, 166-172	2.4	154
162	Anakinra in a Cohort of Children with Chronic Nonbacterial Osteomyelitis. *Journal of Rheumatology*, **2017**, 44, 1231-1238	4.1	20
161	Inflammatory events during food protein-induced enterocolitis syndrome reactions. *Pediatric Allergy and Immunology*, **2017**, 28, 464-470	4.2	24
160	ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis. *RMD Open*, **2017**, 3, e000441	5.9	12
159	Use of a mouse model to identify a blood biomarker for IFN□activity in pediatric secondary hemophagocytic lymphohistiocytosis. *Translational Research*, **2017**, 180, 37-52.e2	11	35
158	THU0509 Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial **2017**,		2

157	Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. *Best Practice and Research in Clinical Rheumatology*, **2017**, 31, 505-516	5.3	32
156	NGF and Its Receptors in the Regulation of Inflammatory Response. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	120
155	Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis. *Journal of the Pediatric Infectious Diseases Society*, **2016**, 5, 76-9	4.8	4
154	Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 14384-14389	11.5	107
153	OP0217 Adjudication of Infections in The Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated with Biologic Agents and/or Methotrexate. *Annals of the Rheumatic Diseases*, **2016**, 75, 139.1-139	2.4	
152	THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). *Annals of the Rheumatic Diseases*, **2016**, 75, 397.3-398	2.4	1
151	Systemic Juvenile Idiopathic Arthritis **2016**, 205-216.e6		13
150	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *RMD Open*, **2016**, 2, e000161	5.9	46
149	Macrophage activation syndrome in the era of biologic therapy. *Nature Reviews Rheumatology*, **2016**, 12, 259-68	8.1	209
148	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Annals of the Rheumatic Diseases*, **2016**, 75, 481-9	2.4	247
147	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. *Frontiers in Pharmacology*, **2016**, 7, 380	5.6	57
146	FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes. *Annals of the Rheumatic Diseases*, **2016**, 75, 616.1-616	2.4	2
145	FRI0488 A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). *Annals of the Rheumatic Diseases*, **2016**, 75, 615.2-616	2.4	3
144	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. *Pediatric Rheumatology*, **2016**, 14, 68	3.5	28
143	A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. *Journal of Immunology*, **2016**, 196, 2492-503	5.3	58
142	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis and Rheumatology*, **2016**, 68, 566-76	9.5	216
141	Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. *EBioMedicine*, **2015**, 2, 285-93	8.8	47
140	Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. *Journal of Rheumatology*, **2015**, 42, 1523-7	4.1	39

139	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Annals of the Rheumatic Diseases*, **2015**, 74, 1110-7	2.4	195
138	The mature/pro nerve growth factor ratio is decreased in the brain of diabetic rats: Analysis by ELISA methods. *Brain Research*, **2015**, 1624, 455-468	3.7	27
137	Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. *Arthritis and Rheumatology*, **2015**, 67, 840-8	9.5	52
136	Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. *Pediatric Rheumatology*, **2015**, 13,	3.5	2
135	THU0508 Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial. *Annals of the Rheumatic Diseases*, **2015**, 74, 384.1-384	2.4	
134	The phenotypic variability of PAPA syndrome: evidence from the Eurofever Registry. *Pediatric Rheumatology*, **2015**, 13,	3.5	3
133	Inflammatory Cytokine response in a cohort of patients carrying novel NLRP12 variants. *Pediatric Rheumatology*, **2015**, 13, O23	3.5	78
132	SAT0483 Tapering and Withdrawal of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results from an Alternative Dosing Regimen in the Tender Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 835.1-835	2.4	
131	FRI0323 Cronic Non-Bacterial Osteomyelitis (CNO) in a Cohort of Pediatric Patients: Clinical, Biological and Radiological Response to Treatment with Anakinra. *Annals of the Rheumatic Diseases*, **2015**, 74, 541.2-541	2.4	
130	OP0134 Increased Muscle Interferon-□Expression Levels in Juvenile Dermatomyositis. *Annals of the Rheumatic Diseases*, **2015**, 74, 119.1-119	2.4	
129	Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. *Arthritis and Rheumatology*, **2015**, 67, 3037-46	9.5	153
128	OP0062 The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Serious Adverse Events. The 5882 Pharmachild Cohort. *Annals of the Rheumatic Diseases*, **2015**, 74, 91-91	2.4	1
127	OP0008 Single Center Experience in Next Generation Sequencing for Genetic Diagnosis of Autoinflammatory Disorders (AIDS). *Annals of the Rheumatic Diseases*, **2015**, 74, 67.1-67	2.4	
126	S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH. *Pediatric Rheumatology*, **2015**, 13,	3.5	2
125	Anti interferon-gamma (IFN)□monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. *Pediatric Rheumatology*, **2015**, 13,	3.5	8
124	High levels of interferon-gamma (IFN)□in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFN□production in MAS. *Pediatric Rheumatology*, **2015**, 13,	3.5	3
123	Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra. *Pediatric Rheumatology*, **2015**, 13,	3.5	78
122	Chronic recurrent multifocal osteomyelitis (CRMO): typical patterns of bone involvement on MRI with particular emphasis on Whole Body MRI (WBMRI). *Pediatric Rheumatology*, **2015**, 13,	3.5	2

121	Whole-Body MRI versus bone scintigraphy: which is the best diagnostic tool in patients with chronic recurrent multifocal osteomyelitis (CRMO)?. *Pediatric Rheumatology*, **2015**, 13,	3.5	2
120	PP11. Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year data from tender. *Rheumatology*, **2015**, 54, ii9-ii9	3.9	
119	Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice. *Human Molecular Genetics*, **2015**, 24, 6041-53	5.6	39
118	SAT0325 Chronic Recurrent Multifocal Osteomyelitis (CRMO): Typical Patterns of Bone Involvement on MRI with Particular Emphasis on Whole Body MRI (WBMRI). *Annals of the Rheumatic Diseases*, **2015**, 74, 776.2-776	2.4	
117	A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFN)Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH. *Blood*, **2015**, 126, LBA-3-LBA-3	2.2	44
116	An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. *Osteoporosis International*, **2014**, 25, 681-92	5.3	8
115	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. *Arthritis and Rheumatology*, **2014**, 66, S8-S9	9.5	6
114	Renal involvement in hypocomplementaemic urticarial vasculitis syndrome: a report of three paediatric cases. *Rheumatology*, **2014**, 53, 1409-13	3.9	12
113	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. *Arthritis and Rheumatology*, **2014**, 66, S5-S6	9.5	4
112	Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 1163-9	12.7	57
111	Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. *Journal of Immunology*, **2014**, 192, 3345-54	5.3	77
110	Deregulation of the IL-1axis in chronic recurrent multifocal osteomyelitis. *Pediatric Rheumatology*, **2014**, 12, 30	3.5	55
109	Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation. *European Journal of Pediatrics*, **2014**, 173, 1391-4	4.1	34
108	Kikuchi-Fujimoto disease in patient with systemic phacomatosis pigmentovascularis. *Blood Coagulation and Fibrinolysis*, **2014**, 25, 783-5	1	
107	IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. *PLoS ONE*, **2014**, 9, e107886	3.7	39
106	Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). *Pediatric Rheumatology*, **2014**, 12,	3.5	19
105	A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis. *Pediatric Rheumatology*, **2014**, 12,	3.5	78
104	Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. *Pediatric Rheumatology*, **2014**, 12, P56	3.5	5

103	Repositioning agricultural development in Africa through appropriate technology transfer. *African Journal of Science, Technology, Innovation and Development*, **2014**, 6, 45-50	0.7	1
102	Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model. *Pediatric Rheumatology*, **2014**, 12,	3.5	6
101	A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. *Arthritis and Rheumatology*, **2014**, 66, S222-S223	9.5	
100	A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2014**, 66, S67-S68	9.5	3
99	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. *Arthritis and Rheumatology*, **2014**, 66, S96-S97	9.5	1
98	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. *Arthritis and Rheumatology*, **2014**, 66, S83-S84	9.5	11
97	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2014**, 66, S23-S24	9.5	3
96	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. *Arthritis and Rheumatology*, **2014**, 66, S17-S18	9.5	4
95	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. *Arthritis and Rheumatology*, **2014**, 66, S80-S81	9.5	4
94	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. *Pediatric Rheumatology*, **2014**, 12,	3.5	4
93	Clinical presentation and cytokine production abnormalities in a cohort of patients carrying NLRP12 gene variants. *Pediatric Rheumatology*, **2014**, 12, P71	3.5	78
92	The macrophage migration inhibitory factor -173G/C polymorphism is not significantly associated with necrotizing enterocolitis in preterm infants. *Journal of Pediatric Surgery*, **2013**, 48, 1499-502	2.6	4
91	Acute rheumatic fever with chorea. *Archives of Disease in Childhood*, **2013**, 98, 203	2.2	
90	Monocytes and macrophages as biomarkers for the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts. *Molecular and Cellular Neurosciences*, **2013**, 56, 307-21	4.8	14
89	Tocilizumab for systemic juvenile idiopathic arthritis. *New England Journal of Medicine*, **2013**, 368, 1256-7	59.2	11
88	Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. *Journal of Rheumatology*, **2013**, 40, 761-7	4.1	49
87	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Annals of the Rheumatic Diseases*, **2013**, 72 Suppl 2, ii2-34	2.4	96
86	OP0175 The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years. *Annals of the Rheumatic Diseases*, **2013**, 71, 114.1-114	2.4	

85	FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. *Annals of the Rheumatic Diseases*, **2013**, 71, 425.1-425	2.4	6
84	Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. *European Journal of Paediatric Neurology*, **2012**, 16, 301-3	3.8	15
83	An international registry on autoinflammatory diseases: the Eurofever experience. *Annals of the Rheumatic Diseases*, **2012**, 71, 1177-82	2.4	121
82	c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. *Nature Communications*, **2012**, 3, 630	17.4	76
81	Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. *Neurology*, **2012**, 78, 1309-14	6.5	34
80	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *New England Journal of Medicine*, **2012**, 367, 2385-95	59.2	577
79	Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. *Arthritis and Rheumatism*, **2012**, 64, 1680-8		87
78	Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. *Journal of Rheumatology*, **2012**, 39, 1287-90	4.1	29
77	Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention. *Heart*, **2012**, 98, 1738-42	5.1	39
76	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Annals of the Rheumatic Diseases*, **2012**, 71 Suppl 2, i2-45	2.4	62
75	Association between mannose-binding lectin gene polymorphisms and necrotizing enterocolitis in preterm infants. *Journal of Pediatric Gastroenterology and Nutrition*, **2012**, 55, 160-5	2.8	19
74	SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS **2011**, 236-248		14
73	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care and Research*, **2011**, 63, 929-36	4.7	277
72	Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. *Journal of Bone and Mineral Research*, **2011**, 26, 1891-903	6.3	99
71	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. *Annals of the Rheumatic Diseases*, **2011**, 70 Suppl 1, i2-36	2.4	58
70	A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia. *Pediatric Research*, **2011**, 69, 142-7	3.2	24
69	Performance of a component-based allergen-microarray in the diagnosis of cow milk and hen egg allergy. *Clinical and Experimental Allergy*, **2010**, 40, 1561-70	4.1	72
68	Interleukin-1 and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. *Molecular Medicine*, **2010**, 16, 552-7	6.2	75

67	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Annals of the Rheumatic Diseases*, **2010**, 69 Suppl 1, i2-29	2.4	102
66	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. *Rheumatology*, **2010**, 49, 441-9	3.9	169
65	Role of mannose-binding lectin in nosocomial sepsis in critically ill neonates. *Human Immunology*, **2010**, 71, 1084-8	2.3	30
64	Relapsing polychondritis: new therapeutic strategies with biological agents. *Rheumatology International*, **2010**, 30, 691-3	3.6	24
63	The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. *Hormone Research*, **2009**, 72 Suppl 1, 26-9		17
62	Mechanisms inducing low bone density in Duchenne Muscular Dystrophy. *Bone*, **2009**, 44, S237-S238	4.7	4
61	Targeting interleukin-6 in pediatric rheumatic diseases. *Current Opinion in Rheumatology*, **2009**, 21, 533-7	5.3	23
60	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of the Rheumatic Diseases*, **2008**, 67 Suppl 3, iii2-25	2.4	81
59	Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome. *Pediatric Nephrology*, **2008**, 23, 743-8	3.2	22
58	Low serum levels of mannose binding lectin are a risk factor for neonatal sepsis. *Pediatric Research*, **2007**, 61, 325-8	3.2	48
57	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. *Acta Paediatrica, International Journal of Paediatrics*, **2007**, 91, 246-247	3.1	8
56	Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. *Arthritis and Rheumatism*, **2006**, 54, 3551-63		234
55	Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 653-9	6.9	53
54	Impact of chronic inflammation on bone during childhood. *Future Rheumatology*, **2006**, 1, 455-464		
53	ELISA qualitative screening of chloramphenicol in muscle, eggs, honey and milk: method validation according to the Commission Decision 2002/657/EC criteria. *Analytica Chimica Acta*, **2005**, 535, 43-48	6.6	77
52	The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. *Leukemia*, **2005**, 19, 2346-7	10.7	21
51	Serum cytokine levels in GH-deficient children during substitutive GH therapy. *European Journal of Endocrinology*, **2005**, 152, 207-10	6.5	25
50	Increased risk of invasive meningococcal disease, pregnancy, and confounding. *Pediatrics*, **2005**, 116, 798-9; author reply 799	7.4	16

49	Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2004**, 39, 540-4	2.8	32
48	A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2004**, 50, 1604-10		115
47	Industrial Synthesis of 4-Chloro,11-arylestradiol: How to Circumvent a Poor Diastereoselectivity. *Organic Process Research and Development*, **2004**, 8, 219-228	3.9	6
46	Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. *Journal of Pediatrics*, **2004**, 145, 851-5	3.6	101
45	203 Low Mannose Binding Lectin (MBL) Serum Levels And Hospital Acquired Infections (HAI) in Neonates in a Neonatal Intensive Care Unit (NICU). *Pediatric Research*, **2004**, 56, 498-498	3.2	
44	Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. *Journal of Rheumatology*, **2004**, 31, 795-800	4.1	28
43	Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2003**, 48, 1398-407		156
42	High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. *Clinical and Experimental Immunology*, **2003**, 131, 355-63	6.2	12
41	Stimulating effect of growth hormone on cytokine release in children. *European Journal of Endocrinology*, **2003**, 149, 397-401	6.5	26
40	Increased expression of alpha(1,3)-fucosyltransferase-VII and P-selectin binding of synovial fluid T cells in juvenile idiopathic arthritis. *Journal of Rheumatology*, **2003**, 30, 1611-5	4.1	7
39	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 232-7		60
38	Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 2402-9		207
37	Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 2721-9		57
36	Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. *Arthritis and Rheumatism*, **2002**, 46, 3015-25		47
35	Role of interleukin-6 in growth failure: an animal model. *Hormone Research in Paediatrics*, **2002**, 58 Suppl 1, 24-7	3.3	27
34	Reciprocal interactions between the GH/IGF-I system and cytokines. *NeuroImmune Biology*, **2002**, 27-35		1
33	Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. *European Cytokine Network*, **2002**, 13, 99-103	3.3	8
32	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. *Acta Paediatrica, International Journal of Paediatrics*, **2002**, 91, 246-7	3.1	2

31	In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. *Journal of Immunology*, **2001**, 166, 4334-40	5.3	43
30	Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. *Endocrinology*, **2001**, 142, 4818-26	4.8	130
29	Juvenile idiopathic arthritis: will etanercept be an improvement over current therapies?. *BioDrugs*, **2000**, 14, 93-8	7.9	
28	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. *Rheumatology*, **1999**, 38, 773	3.9	11
27	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. *Arthritis and Rheumatism*, **1999**, 42, 807-11		63
26	Interleukin 6 is required for the development of collagen-induced arthritis. *Journal of Experimental Medicine*, **1998**, 187, 461-8	16.6	495
25	Cisternal CSF levels of cytokines after subarachnoid hemorrhage. *Neurological Research*, **1998**, 20, 337-42	2.7	124
24	Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. *Rheumatology*, **1997**, 36, 581-8	3.9	25
23	Cytokines in juvenile rheumatoid arthritis. *Current Opinion in Rheumatology*, **1997**, 9, 428-33	5.3	34
22	Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. *Journal of Clinical Investigation*, **1997**, 99, 643-50	15.9	370
21	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. *Journal of Pediatrics*, **1996**, 128, 275-8	3.6	124
20	Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. *Blood*, **1996**, 87, 4824-4830	2.2	146
19	Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. *Journal of Pediatric Gastroenterology and Nutrition*, **1995**, 20, 23-7	2.8	46
18	Lack of temporal association of iridocyclitis with IgG reactivities to core histones and nucleosome subparticles in pauciarticular juvenile chronic arthritis. *Rheumatology*, **1995**, 34, 507-11	3.9	9
17	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. *American Journal of Hematology*, **1994**, 46, 189-93	7.1	32
16	Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. *Journal of Pediatrics*, **1994**, 124, 742-4	3.6	46
15	Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. *Journal of Pediatrics*, **1994**, 124, 561-5	3.6	49
14	Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. *Journal of Clinical Investigation*, **1994**, 93, 2114-9	15.9	188

13	CD5-positive B cells in type 1 (insulin-dependent) diabetic children. *Diabetes Research and Clinical Practice*, **1993**, 19, 17-22	7.4	8
12	Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. *Archives of Disease in Childhood*, **1993**, 69, 232-5	2.2	36
11	Anti-DNA antibodies in the primary antiphospholipid syndrome. *Rheumatology*, **1993**, 32, 1028	3.9	3
10	Secondary thrombocytosis. *Archives of Disease in Childhood*, **1993**, 69, 170-1	2.2	1
9	Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. *Gynecologic and Obstetric Investigation*, **1993**, 36, 39-41	2.5	26
8	Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. *Arthritis and Rheumatism*, **1991**, 34, 1158-63		285
7	Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. *Blood*, **1991**, 77, 1248-1255	2.2	2
6	Decreased fibrinolytic activity in juvenile chronic arthritis. *Annals of the Rheumatic Diseases*, **1990**, 49, 973-5	2.4	7
5	Effects of Retinoic Acid on TGF Receptor Expression in HL-60 Cells. *Annals of the New York Academy of Sciences*, **1990**, 593, 310-312	6.5	3
4	Synergy between Transforming Growth Factor- and Tumor Necrosis Factor- In the Induction of Monocytic Differentiation of Human Leukemic Cell Linesa. *Annals of the New York Academy of Sciences*, **1990**, 593, 334-337	6.5	
3	Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. *Annals of the Rheumatic Diseases*, **1989**, 48, 582-5	2.4	2
2	Morphology of the gastric mucosa, gastric secretion and serum gastrin concentration following a test meal. *Digestion*, **1978**, 17, 18-28	3.6	2
1	Effect of IL-6 on IGF Binding Protein-3: A Study in IL-6 Transgenic Mice and in Patients with Systemic Juvenile Idiopathic Arthritis		39